Opinion
The new obesity breakthrough drugs
Semaglutide and other drugs for weight loss were being developed for improving glucose regulation and unexpectedly were found to achieve...
Opinion
The body of evidence for Paxlovid therapy
For older patients, we should be thinking of why we should be using Paxlovid rather than the reason not to treat.
Article
The sad story of Vioxx, and what we should learn from it
The withdrawal of rofecoxib (Vioxx) has important implications both for patients with arthritis and for the pharmaceutical field in general.
Article
Using C-reactive protein to assess cardiovascular disease risk
CRP is now a recognized cardiac test. But who should be tested?
Article
Thyrotoxicosis and the cardiovascular system: Subtle but serious effects
One should suspect thyrotoxicosis in patients with palpitations, tachycardia, exercise intolerance, or dyspnea on exertion.
Article
COX-2 inhibitors and cardiovascular risk: We defend our data and suggest caution
Our study had limitations, but we believe our hypothesis is plausible, our methods were valid, and our conclusions are sound.
Article
C-reactive protein: A 'golden marker' for inflammation and coronary artery disease
Elevated levels of CRP are associated with increased cardiovascular risk.
Article
The pathogenesis and spectrum of acute coronary syndromes: From plaque formation to thrombosis
Acute coronary syndromes occur when vulnerable plaque ruptures, leading to acute thrombosis. With an illustration explaining this chain of events...
Article
Reperfusion for acute myocardial infarction: 1997 and beyond
The optimal thrombolytic therapy will be a cocktail of several thrombolytic, antithrombotic, and antiplatelet agents, each of which attacks...